What is Third Arc Bio?
Third Arc Bio is a clinical-stage biotechnology firm dedicated to designing multifunctional antibody medicines. The company focuses on modulating immune synapses within solid tumors and inflammatory disease contexts. By uniting advanced discovery platforms with robust translational expertise, Third Arc Bio aims to deliver groundbreaking biologic therapies to patients in need.
How much funding has Third Arc Bio raised?
Third Arc Bio has raised a total of $217M across 2 funding rounds:
Series A
$165M
Series A
$52M
Series A (2024): $165M with participation from Vida Ventures, Hillhouse Investments, and Cormorant Asset Management Puerto Rico
Series A (2026): $52M led by Andreessen Horowitz
Key Investors in Third Arc Bio
Vida Ventures
Vida Ventures is a life sciences investment firm founded by experts passionate about advancing biomedical breakthroughs. They focus on building and funding transformative innovations with the potential to significantly impact patient care.
Hillhouse Investments
Hillhouse Investments operates within the Venture Capital & Private Equity sector, focusing on strategic investments in promising companies.
Cormorant Asset Management Puerto Rico
Cormorant Asset Management Puerto Rico LLC is an entity involved in the HR & Staffing industry, indicating a diverse investment portfolio.
What's next for Third Arc Bio?
The substantial enterprise-level capital infusion positions Third Arc Bio for accelerated growth and the advancement of its therapeutic pipeline. This strategic backing is expected to fuel further research and development, potentially enabling the company to expand its clinical trials and move closer to commercializing its innovative treatments for challenging oncological and inflammatory conditions. The company's focus on immune synapse modulation suggests a forward-thinking approach to immunotherapy.
See full Third Arc Bio company page
